ArticleThe journal of allergy and clinical immunology. In practice
Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria.
Article in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 51 citations in OpenAlex.
- Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond.The journal of allergy and clinical immunology. In practice · 2026Review
- The Urticaria Voices Study: Physicians' Perspectives on the Real-World Patient Burden, Treatments, and Outcomes in Chronic Spontaneous Urticaria.Dermatology and therapy · 2025Article
- Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's.The World Allergy Organization journal · 2025Review
- A prospective observational study correlating possible novel biomarkers with disease severity and antihistamine response in chronic spontaneous urticaria.Asia Pacific allergy · 2024Article
- Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria.The World Allergy Organization journal · 2024Article
- Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data.Life (Basel, Switzerland) · 2023Review
- Successful management of chronic urticaria and food allergies in a pediatric population using integrative traditional Chinese medicine therapy: a case series.Clinical and molecular allergy : CMA · 2022Article
- Prevalence, Clinical Manifestations, Treatment, and Clinical Course of Chronic Urticaria in Elderly: A Systematic Review.Journal of asthma and allergy · 2022Review
- Biomarkers of Gut Microbiota in Chronic Spontaneous Urticaria and Symptomatic Dermographism.Frontiers in cellular and infection microbiology · 2021Article
- Chronic urticaria and thyroid pathology.The World Allergy Organization journal · 2020Article
- Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.Clinical and translational allergy · 2019Article
- Chronic Urticaria: Comparisons of US, European, and Asian Guidelines.Current allergy and asthma reports · 2018Review
- Guideline of Chronic Urticaria Beyond.Allergy, asthma & immunology research · 2016Review
- Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines.Current allergy and asthma reports · 2015Review
- Resistant Chronic Spontaneous Urticaria - A Case Series Narrative Review of Treatment Options.Allergy & rhinology (Providence, R.I.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIdentifying clinical characteristics of patients with chronic urticaria (CU) responsive to medication may help guide clinicians select treatment.
objectiveThe objective of this study was to investigate patient characteristics and medication use associated with urticaria control.
methodsA retrospective longitudinal chart review of adult patients with CU was conducted at a multisite allergy practice. Inclusion criteria required at least 4 CU office visits to allow for pre- and posttreatment assessment. Control corresponding to medication(s) used was assessed each visit. Univariate analysis followed by multiple logistic regression was performed.
resultsA total of 221 patients with CU were included; 140 (63%) achieved complete control. The average time to control was 1.4 ± 2.7 years, which required 1-3 classes of medications. Dermatographia odds ratio (OR) = 1.85 (95% CI 1.3-2.7) or other physical urticarias, OR = 1.51 (1-2.4) and neutrophilic infiltrates on skin biopsy were markers of poor control. Thyroid autoantibodies were associated with better control using an H1-antihistamine. Whereas 22% were controlled on a second-generation H1-receptor antagonist plus a leukotriene receptor antagonist (LTRA), an additional 33% were controlled when cyclosporine was added. Use of a first or second H1-antagonist or LTRA was associated with a 3.5-16.9 times higher odds of complete CU control in those with dermatographia. The odds of achieving control for other forms of physical urticaria was greatest when colchicine was added (aOR = 32.6 [12.7-83.2]).
conclusionsPatient-specific CU characteristics associated with medication-disease control may be useful for selecting treatment regimens. A subset of CU patients remains poorly controlled that indicates an unmet need for novel therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.